Invasive fungal infections in pediatric hematopoietic stem cell transplant patients

Tiffany Simms-Waldrip, Galit Rosen, Karin Nielsen-Saines, Alan Ikeda, Berkley Brown, Theodore Moore

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Pediatric hematopoietic stem cell transplant (HSCT) recipients are at high risk of invasive fungal infections (IFIs). Methods: To characterize IFIs and changes in fungal organisms over time in pediatric HSCT patients, we performed a retrospective cohort study of all HSCTs performed in pediatric patients at UCLA between 1991 and 2006. Results: In all, 318 patients underwent 324 HSCT transplants over the 15-year period and 69 unique fungal infections were identified in 47 transplant patients. The overall incidence of fungal infections in HSCT recipients was 14.5%, with predominant organisms including Candida species (51%) and Aspergillus species (26%), with Candida albicans accounting for 18.8% of all fungal species. The distribution of organisms over time demonstrated a strong trend towards an increase in rare molds in more recent years. The respiratory tract was the main site of infection (52.6%), with urine and blood also noted as significant sites. Of all deaths in the patients with IFIs, fungal-related mortality accounted for 67.6% of deaths. Conclusions: HSCT patients have a much higher risk of fungal infections with rarer organisms becoming more prevalent, a finding likely linked to evolving antifungal practices over time. This emphasizes the need for the development and implementation of improved diagnostic, prophylactic, and therapeutic strategies to improve patient survival.

Original languageEnglish (US)
Pages (from-to)218-224
Number of pages7
JournalInfectious Diseases
Volume47
Issue number4
DOIs
StatePublished - 2015

Fingerprint

Hematopoietic Stem Cells
Pediatrics
Transplants
Mycoses
Aspergillus
Invasive Fungal Infections
Candida albicans
Candida
Respiratory System
Cohort Studies
Fungi
Retrospective Studies
Urine
Survival
Mortality
Incidence
Infection

Keywords

  • Aspergillus
  • Candida
  • Fungal infections
  • HSCT
  • Pediatric
  • Stem cell transplant

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Medicine(all)

Cite this

Invasive fungal infections in pediatric hematopoietic stem cell transplant patients. / Simms-Waldrip, Tiffany; Rosen, Galit; Nielsen-Saines, Karin; Ikeda, Alan; Brown, Berkley; Moore, Theodore.

In: Infectious Diseases, Vol. 47, No. 4, 2015, p. 218-224.

Research output: Contribution to journalArticle

Simms-Waldrip, Tiffany ; Rosen, Galit ; Nielsen-Saines, Karin ; Ikeda, Alan ; Brown, Berkley ; Moore, Theodore. / Invasive fungal infections in pediatric hematopoietic stem cell transplant patients. In: Infectious Diseases. 2015 ; Vol. 47, No. 4. pp. 218-224.
@article{cce71569bb8045ff9b904fa25a10a899,
title = "Invasive fungal infections in pediatric hematopoietic stem cell transplant patients",
abstract = "Background: Pediatric hematopoietic stem cell transplant (HSCT) recipients are at high risk of invasive fungal infections (IFIs). Methods: To characterize IFIs and changes in fungal organisms over time in pediatric HSCT patients, we performed a retrospective cohort study of all HSCTs performed in pediatric patients at UCLA between 1991 and 2006. Results: In all, 318 patients underwent 324 HSCT transplants over the 15-year period and 69 unique fungal infections were identified in 47 transplant patients. The overall incidence of fungal infections in HSCT recipients was 14.5{\%}, with predominant organisms including Candida species (51{\%}) and Aspergillus species (26{\%}), with Candida albicans accounting for 18.8{\%} of all fungal species. The distribution of organisms over time demonstrated a strong trend towards an increase in rare molds in more recent years. The respiratory tract was the main site of infection (52.6{\%}), with urine and blood also noted as significant sites. Of all deaths in the patients with IFIs, fungal-related mortality accounted for 67.6{\%} of deaths. Conclusions: HSCT patients have a much higher risk of fungal infections with rarer organisms becoming more prevalent, a finding likely linked to evolving antifungal practices over time. This emphasizes the need for the development and implementation of improved diagnostic, prophylactic, and therapeutic strategies to improve patient survival.",
keywords = "Aspergillus, Candida, Fungal infections, HSCT, Pediatric, Stem cell transplant",
author = "Tiffany Simms-Waldrip and Galit Rosen and Karin Nielsen-Saines and Alan Ikeda and Berkley Brown and Theodore Moore",
year = "2015",
doi = "10.3109/00365548.2014.985709",
language = "English (US)",
volume = "47",
pages = "218--224",
journal = "Infectious Diseases",
issn = "2374-4235",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Invasive fungal infections in pediatric hematopoietic stem cell transplant patients

AU - Simms-Waldrip, Tiffany

AU - Rosen, Galit

AU - Nielsen-Saines, Karin

AU - Ikeda, Alan

AU - Brown, Berkley

AU - Moore, Theodore

PY - 2015

Y1 - 2015

N2 - Background: Pediatric hematopoietic stem cell transplant (HSCT) recipients are at high risk of invasive fungal infections (IFIs). Methods: To characterize IFIs and changes in fungal organisms over time in pediatric HSCT patients, we performed a retrospective cohort study of all HSCTs performed in pediatric patients at UCLA between 1991 and 2006. Results: In all, 318 patients underwent 324 HSCT transplants over the 15-year period and 69 unique fungal infections were identified in 47 transplant patients. The overall incidence of fungal infections in HSCT recipients was 14.5%, with predominant organisms including Candida species (51%) and Aspergillus species (26%), with Candida albicans accounting for 18.8% of all fungal species. The distribution of organisms over time demonstrated a strong trend towards an increase in rare molds in more recent years. The respiratory tract was the main site of infection (52.6%), with urine and blood also noted as significant sites. Of all deaths in the patients with IFIs, fungal-related mortality accounted for 67.6% of deaths. Conclusions: HSCT patients have a much higher risk of fungal infections with rarer organisms becoming more prevalent, a finding likely linked to evolving antifungal practices over time. This emphasizes the need for the development and implementation of improved diagnostic, prophylactic, and therapeutic strategies to improve patient survival.

AB - Background: Pediatric hematopoietic stem cell transplant (HSCT) recipients are at high risk of invasive fungal infections (IFIs). Methods: To characterize IFIs and changes in fungal organisms over time in pediatric HSCT patients, we performed a retrospective cohort study of all HSCTs performed in pediatric patients at UCLA between 1991 and 2006. Results: In all, 318 patients underwent 324 HSCT transplants over the 15-year period and 69 unique fungal infections were identified in 47 transplant patients. The overall incidence of fungal infections in HSCT recipients was 14.5%, with predominant organisms including Candida species (51%) and Aspergillus species (26%), with Candida albicans accounting for 18.8% of all fungal species. The distribution of organisms over time demonstrated a strong trend towards an increase in rare molds in more recent years. The respiratory tract was the main site of infection (52.6%), with urine and blood also noted as significant sites. Of all deaths in the patients with IFIs, fungal-related mortality accounted for 67.6% of deaths. Conclusions: HSCT patients have a much higher risk of fungal infections with rarer organisms becoming more prevalent, a finding likely linked to evolving antifungal practices over time. This emphasizes the need for the development and implementation of improved diagnostic, prophylactic, and therapeutic strategies to improve patient survival.

KW - Aspergillus

KW - Candida

KW - Fungal infections

KW - HSCT

KW - Pediatric

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=84983122159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983122159&partnerID=8YFLogxK

U2 - 10.3109/00365548.2014.985709

DO - 10.3109/00365548.2014.985709

M3 - Article

C2 - 25650728

AN - SCOPUS:84983122159

VL - 47

SP - 218

EP - 224

JO - Infectious Diseases

JF - Infectious Diseases

SN - 2374-4235

IS - 4

ER -